

---

# Author Correction: Protein kinases: drug targets for immunological disorders

---

Correction to: *Nature Reviews Immunology*  
<https://doi.org/10.1038/s41577-023-00877-7>,  
published online 15 May 2023.

---

<https://doi.org/10.1038/s41577-023-00976-5>

---

Published online: 27 November 2023

---

 Check for updates

---

**Leslie Castelo-Soccio** , **Hanna Kim** , **Massimo Gadina**,  
**Pamela L. Schwartzberg** , **Arian Laurence** & **John J. O'Shea** 

---

In the version of the article initially published, there was an error in Fig. 2 where pembrolizumab was included but has been removed as it is not a protein kinase inhibitor. In Table 3, a dividing line between Povorcitinib and Tofacitinib was missing and has now been added. These corrections have been made to the HTML and PDF versions of the article.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023